We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New COVID-19 Assay Proves as Reliable as Laboratory PCR Test and Ideal for Inexpensive POC Diagnosis

By LabMedica International staff writers
Posted on 04 Jan 2022

A potential at-home COVID-19 test is just as good as laboratory PCR tests, according to preclinical data. More...

Researchers at the University of Illinois Chicago (Chicago, IL, USA) have designed a high-quality assay that can be used in at-home tests for rapid COVID-19 screening. Results from an early preclinical study suggest that tests with the new assay may be just as reliable as the laboratory-based molecular tests - called PCR tests - used by hospitals for clinical diagnostics.

Assay reagents create a chemical reaction when mixed with a biological sample containing a virus or other marker. For example, an at-home pregnancy test consists of assay reagents that react to pregnancy hormones in a urine sample. In laboratory molecular tests, scientists mix samples with assay reagents in a highly controlled process. Because the reaction conditions (like temperature) are tightly controlled, the tests are both sensitive and selective, meaning the chance of false positives or false negatives is very low. However, these laboratory tests can be expensive and are not accessible in all communities and field settings. The challenge with at-home and field tests is that they need assay reagents to work under less controlled conditions, which increases the chances for false results or inconclusive tests.

One method, called loop-mediated isothermal amplification (LAMP), which uses six DNA primers for pathogen detection, has shown promise for other pathogens, like malaria, but has not been efficiently applied to COVID-19. The UIC researchers who developed the new COVID-19 assay first created and applied a bioinformatics algorithm to identify the best potential DNA primer combinations for reliably detecting SARS-CoV-2, the virus that causes COVID-19, with the LAMP method. Then, the researchers ran a series of simulations to optimize the conditions under which the potential DNA primer combinations worked best in the field environments.

After using their analysis to develop a testing method using the DNA primers and conditions, the team designed experiments to see how the test performed. In experiments, the researchers processed artificial samples and human samples with a standard PCR test and with their new test. When the results were compared, the researchers not only saw significant improvement in the efficiency of their test over others using the LAMP method to detect the virus but also that it was comparable to more expensive gold standard PCR tests. The researchers concluded that the new LAMP assays were as effective as standard PCR assays in SARS-CoV-2 detection and that their new assays have unique advantages, like speed and direct detection of viral RNA in saliva, that make the test “ideal for inexpensive point-of-care diagnosis.”

The lab-based study showed that their test works, but the researchers will need to validate the test in further studies with a greater number of samples from real patients. They hope that by summer they will have conducted a study including about 1,500 patient samples. If the study validates the test, the data will be submitted with an application to U.S. Food and Drug Administration for Emergency Use Authorization.

“Having fast and easy-to-use tests for COVID-19 is critical, especially in the communities that have low rates of vaccination and low access to health care services, including COVID-19 surveillance and diagnostic testing,” said Xiaowei Wang, UIC professor of pharmacology and bioengineering. “The current crisis has created an unprecedented need for rapid tests that are highly sensitive and the sooner we can develop better technology and testing options, the better it will be for everyone.”

Related Links:
University of Illinois Chicago 


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.